Acetylcysteine Patent Expiration
Acetylcysteine is Used for treating acetaminophen overdose with acetylcysteine solutions to provide a reduction in side effects for human patients. It was first introduced by Apothecon Inc Div Bristol Myers Squibb
Acetylcysteine Patents
Given below is the list of patents protecting Acetylcysteine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Acetadote | US8952065 | Acetylcysteine composition and uses thereof | Feb 10, 2035 | Apotex |
| Cetylev | US8747894 | Effervescent compositions containing N-acetylcysteine | May 08, 2032 | Arbor Pharms Llc |
| Cetylev | US9427421 | Effervescent compositions containing N-acetylcysteine | May 08, 2032 | Arbor Pharms Llc |
| Cetylev | US9561204 | Effervescent compositions containing N-acetylcysteine | May 08, 2032 | Arbor Pharms Llc |
| Acetadote | US8722738 | Acetycysteine compositions and methods of use thereof | Apr 06, 2032 | Apotex |
| Acetadote | US9327028 | Acetylcysteine compositions and methods of use thereof | Jul 21, 2031 | Apotex |
| Acetadote | US8148356 | Acetylcysteine composition and uses therefor |
May 21, 2026
(Expired) | Apotex |
| Acetadote | US8399445 | Acetylcysteine composition and uses thereof |
Aug 24, 2025
(Expired) | Apotex |
| Acetadote | US8653061 | Acetylcysteine composition and uses thereof |
Aug 24, 2025
(Expired) | Apotex |
Acetylcysteine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Acetylcysteine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
